Biogen continues with new data in adults and infants

CAMBRIDGE, Mass., April 12, 2019 (GLOBE NEWSWIRE)Biogen (Nasdaq: BIIB) today announced it will present new data illustrating the rapidly progressive nature of spinal muscular atrophy (SMA) in adults, adolescents and older children at the Muscular Dystrophy Association (MDA) Clinical and Scientific Conference in Orlando, Florida (April 13-17, 2019). Other Biogen presentations will highlight the benefits of pre-symptomatic treatment with data from the NURTURE study, part of the SPINRAZA® (nusinersen) global clinical trial program, and findings on the role of neurofilament as a potential biomarker for predicting motor function in SMA.

Argentina approves Spinraza for all SMA Types

Congrats to Argentina, Argentina have approved Spinraza for all SMA types without limitations, hurray. These children, adults get the chance for a better life.

In the next few days comes the management plan. This is a historically victory. Rich country like Denmark, which still refuses therapy for its patients.

All of Scandinavia countries has an age restriction.
Argentina can be proud of itself

Countries like Denmark (only for SMA type 1, SMA type 2 under 6 age,
Norway (SMA typ1) 
Sweden all SMA patients, but only under 18 years.

In Europe, there are few countries like Germany that have all SMA Patients access to Spinraza, without any age limit.